CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 13,021 enrolled
Drug / intervention
PDE5 inhibitor +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05039086
NCT05039086N/ACompleted
CompareCT.gov

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- PDE5

Brigham and Women's Hospital·observational·Posted Sep 9, 2021·Updated Aug 6, 2025

In Brief

An observational study evaluating PDE5 inhibitor and Endothelin Receptor Antagonists for Pulmonary Arterial Hypertension. Completed, enrolled 13,021 participants across 1 site.

Detailed Summary

This study aims to evaluate the comparative risk of dementia/Alzheimer's disease onset between patients treated with medications that target specific metabolic pathways and patients treated with alternative medications for the same indication.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Arterial Hypertension
CountriesUnited States
CollaboratorsNational Institute on Aging (NIA), Rutgers University, Johns Hopkins University

Timeline

N/ACompletedFinished
20222023202420252026
First PostedSep 9, 2021
Enrollment StartSep 1, 2021
Primary CompletionSep 30, 2021
Study CompletionOct 4, 2022
TodayJul 2, 2026
Enrollment to primary: 29 daysPosted 4.8 years ago

Interventions

PDE5 inhibitordrug

PDE5 inhibitors (sildenafil, tadalafil) claim is used as the exposure group.

Endothelin Receptor Antagonistsdrug

Endothelin receptor antagonists (bosentan, ambrisentan, macitentan) claim is used as the reference group.